New surgical technique is effective for keratoconus

Article

For the management of keratoconus, diamond-knife?assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a recently published study.

For the management of keratoconus, diamond-knife–assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a study recently published in the Journal of Cataract & Refractive Surgery.

Diamond-knife–assisted DALK is the most recent variation of DALK for cornea replacement, and is preceded by the big-bubble technique, in which air is injected into the corneal stroma to isolate Desçemet's membrane.

Researchers performed diamond-knife–assisted DALK in 19 eyes and big-bubble DALK in 11 eyes successfully. At 6 months, mean corrected distance visual acuity (CDVA) improved significantly, from 1.87 logMAR to 0.23 logMAR (P = 0.05). In addition, mean keratometry improved from 65.99 D to 45.13 D, and the mean keratometric cylinder improved from 7.99 D to 2.87 D (P = 0.05 for both).

Postoperatively, mean refractive astigmatism was 2.55 D and the mean spherical equivalent was -1.97 D. When comparisons were made between diamond-knife–assisted DALK and big-bubble DALK, the following values were comparable: CDVA (P = 0.06), postoperative keratometry (P = 0.64), refractive cylinder (P = 0.63), and endothelial cell loss (P = 0.11).

All surgeries were completed successfully, and there were no intraoperative or postoperative complications with the diamond-knife–assisted DALK.

To access the abstract of this study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.